dcc-3084
·Code: DCC-3084
dcc-3084: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | Phase 1/Phase 2 |
Clinical Trials (1)
A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Frequently asked questions
Who is developing dcc-3084?
dcc-3084 is being developed by Deciphera Pharmaceuticals, Inc..
How many clinical trials involve dcc-3084?
BioSniper tracks 1 clinical trial involving dcc-3084.
Get deeper analysis on dcc-3084
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis